ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO886

Modeling Based on NefIgArd Two-Year eGFR Total Slope Predicts Long-Term Clinical Benefit of Nefecon in a Real-World IgA Nephropathy (IgAN) Population

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Barratt, Jonathan, College of Medicine Biological Sciences and Psychology, University of Leicester, Leicester, United Kingdom
  • Stone, Andrew M., Stone Biostatistics Ltd., Crewe, United Kingdom
  • Reich, Heather N., Division of Nephrology, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • Lafayette, Richard A., Division of Nephrology, Department of Medicine, Stanford University, Stanford, California, United States

Nefecon, a targeted-release budesonide formulation, is approved for the treatment of patients (pts) with immunoglobulin A nephropathy (IgAN). Data from the full Phase 3 NefIgArd trial showed that 9 months of Nefecon 16 mg/d preserved estimated glomerular filtration rate (eGFR) and reduced urine protein–creatinine ratio (UPCR) vs placebo. These effects were maintained during the 15-month off-drug follow-up period, indicating that Nefecon is disease-modifying. We conducted a modeling analysis to predict the potential long-term benefit of Nefecon on clinical outcome (i.e., a composite endpoint of end stage renal disease, eGFR <15 mL/min/1.73m2, or sustained doubling of serum creatinine) in a real-world IgAN population.


In the final analysis of the NefIgArd trial, there was a treatment benefit in 2-year eGFR total slope of 2.78 mL/min/1.73m2 per year (95% confidence interval [CI] 1.39–4.17) with Nefecon vs placebo (linear spline mixed-effect model). This difference was applied to a published linear regression between treatment effects for the change in 2-year eGFR total slope and the log hazard ratio (HR) of clinical outcome, based on a meta-analysis involving >60K CKD pts (Inker et al. JASN 2019;30:1735-45). Median time to clinical outcome for a reference group receiving supportive standard of care (SoC) only was estimated by modeling long-term registry data from pts at Leicester General Hospital (LGH), UK, matching NefIgArd-recruited pts to individual LGH pt records based on their baseline UPCR and eGFR. Time to clinical outcome for SoC pts was estimated using a Weibull model.


352/364 NefIgArd pts were matched with 886 unique records from 192 LGH pts, which contained 287 clinical outcome event-times from 68 LGH pts. The NefIgArd 2-year eGFR total slope translated to a log HR for clinical outcome of 0.38 (95% CI 0.21–0.63), a 62% risk reduction vs placebo. Median time to clinical outcome was estimated at 9.6 years in SoC pts and 22.4 years in Nefecon-treated pts (median delay 12.8 [95% CI 4.8–27.9] years). 52% of SoC pts were predicted to have a clinical outcome within 10 years vs 24% of Nefecon-treated pts.


Modeling analyses indicate that the clinical benefit seen with Nefecon predicts a substantial delay in progression to kidney failure.


  • Commercial Support – Calliditas Therapeutics